Overview

• A multicenter study in Spain, Sweden and Italy tested 1,767 symptomatic adults (mean age 73) and found blood p‑tau217 measured on the Lumipulse system identified Alzheimer’s with high accuracy.
• Because Lumipulse is already installed in many hospitals and laboratories, clinicians say the assay could enable scalable screening in primary care and reduce reliance on PET scans or lumbar punctures.
• Study authors and experts stress the assay is not yet ready for routine use, noting the need for larger validation studies and formal regulatory review before clinical rollout.
• Contemporary analyses in The Lancet highlight that new monoclonal antibodies such as lecanemab and donanemab can slow early disease (lecanemab by about 27%), underscoring the need for early, accurate diagnosis and health‑system upgrades for monitoring and access.
• In parallel, FIU researchers report elevated TSPO as an early neuroinflammation signal in familial Alzheimer models and human tissue, and they are exploring a lower‑cost blood test and potential therapeutic targeting of this protein.